Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Spis, bevæg dig, live-program til reduktion af kræft- og kroniske sygdommes risiko i undertjente samfund

2. november 2026 opdateret af: City of Hope Medical Center

Reduktion af risiko for kræft og kroniske sygdomme i undertjente lokalsamfund: Spis, bevæg dig, live-program

This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.

II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.

III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.

OUTLINE:

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

347

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Duarte, California, Forenede Stater, 91010
        • City of Hope Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Agrees to group consent at week 1
  • Age over 18
  • Able to speak and understand English and/or Spanish

Exclusion Criteria:

  • Don't agree to group consent at week 1
  • Age younger than 18
  • Not able to speak and understand English and/or Spanish
  • Can't participate in physical activity

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Supportive care (EML program)

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Ancillary studies

Attend EML program sessions

Andre navne:
  • Adfærdskonditionerende terapi
  • Adfærdsændring
  • Ændringer i adfærd eller livsstil
  • Adfærdsterapi
  • Adfærdsmæssige indgreb
  • Adfærdsbehandling
  • Adfærdsmæssige behandlinger

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12
Tidsramme: Baseline and week 12

Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree).

Baseline and week 12
Changes in behavior as measured by questionnaires from baseline to week 12
Tidsramme: Baseline and week 12

Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more".

Baseline and week 12
Changes in height from baseline to week 12
Tidsramme: Baseline to 12 weeks

Height measured in meters

Baseline to 12 weeks
Changes in weight from baseline to week 12
Tidsramme: Baseline to 12 weeks

Weight measured in Kilograms

Baseline to 12 weeks
Changes in waist circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Hip circumference measured in centimeters

Baseline to 12 weeks
Changes in chest circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Chest circumference measured in centimeters

Baseline to 12 weeks
Changes in right upper arm circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Right upper arm circumference measured in centimeters

Baseline to 12 weeks
Changes in left upper arm circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Left upper arm circumference measured in centimeters

Baseline to 12 weeks
Changes in right upper thigh circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Right upper thigh circumference measured in centimeters

Baseline to 12 weeks
Changes in left upper thigh circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Left upper thigh circumference measured in centimeters

Baseline to 12 weeks
Changes in body fat percentage from baseline to week 12
Tidsramme: Baseline to 12 weeks

Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage.

Baseline to 12 weeks
Changes in systolic blood pressure from baseline to week 12
Tidsramme: Baseline to 12 weeks

Systolic blood pressure measured in mmHG

Baseline to 12 weeks
Changes in diastolic blood pressure from baseline to week 12
Tidsramme: Baseline to 12 weeks

Diastolic blood pressure measured in mmHG

Baseline to 12 weeks
Changes in hip circumference from baseline to week 12
Tidsramme: Baseline to 12 weeks

Hip circumference measured in centimeters

Baseline to 12 weeks
Changes in biomarkers
Tidsramme: Baseline to 12 weeks

Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines.

Baseline to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Victoria L Seewaldt, City of Hope Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. marts 2018

Primær færdiggørelse (Anslået)

11. oktober 2027

Studieafslutning (Anslået)

11. oktober 2027

Datoer for studieregistrering

Først indsendt

24. marts 2022

Først indsendt, der opfyldte QC-kriterier

8. juni 2022

Først opslået (Faktiske)

10. juni 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 17410
  • P30CA033572 (U.S. NIH-bevilling/kontrakt)
  • 17410 (Anden identifikator: City of Hope Comprehensive Cancer Center)
  • NCI-2022-00180 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .